Haemophilus Influenzae Type b Conjugate Vaccine (Royal Bio-Pharmaceutical)

b型流感嗜血杆菌结合疫苗（罗益生物制药）

Report date: 2024/12/13 14:52:27

Base Information

Drug NameHaemophilus Influenzae Type b Conjugate Vaccine (Royal Bio-Pharmaceutical)
Drug Alias NameN/A
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Conjugated vaccineVaccines > Biological material > Bacterial vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMeningitisArthritisCellulitis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesRoyal (Wuxi) Bio-Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRoyal (Wuxi) Bio-Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMeningitisArthritisCellulitis +[6] 
Inactive IndicationsHaemophilus Infections

Other Information

ATC CodeN/A
Related LinksN/A